Alice is a Partner of Syncona Investment Management Ltd. She is also Head of Operations at Purespring Therapeutics and works closely with Anaveon. Alice serves as an Observer on the Board of Purespring and Anaveon. Prior to Syncona, Alice was an Investment Banking Analyst within Barclays’ Healthcare M&A team, where she worked on transactions involving healthcare companies. Alice holds a Doctorate degree in Pharmacy from the University of Lille 2 (School of Pharmacy) and a Masters in International Health Policy & Health Economics from the London School of Economics.
- Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual MeetingJune 5, 2023
- Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual MeetingJune 3, 2023
- Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual MeetingApril 18, 2023